Found 7 Peritoneal Cancer trials
A listing of Peritoneal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study will evaluate safety, clinical activity, and PK of ZN-c3 in subjects with platinum-resistant, high grade, serous ovarian, fallopian tube, or primary peritoneal cancer. Part 1a locally advanced/metastatic solid tumors with mutations in MRN complex genes or CCNE1 gene amplification. Part 1b primary peritoneal cancer. Part 2: PROC allocated …
The purpose of this study includes the following: · To test the efficacy and safety of the Study Drug and to find out what effects, good and/or bad, it has on you and your cancer. · To understand how the body absorbs and processes the Study Drug by measuring the …
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may …
Investigate the efficacy and safety of luveltamab tazevibulin compared to IC chemotherapy in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting FOLR1 which is expressed in approximately 80% of recurrent ovarian cancers, and expression is maintained in metastatic foci and in …
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability of luveltamab tazevibulin in …
A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
